Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global Rather Than Vertical-Selective Saccadic Abnormalities in Progressive Supranuclear Palsy.

Annals of clinical and translational neurology·2026
Same author

Exercise as a regulator of glymphatic function.

Trends in neurosciences·2026
Same author

Acute and longitudinal magnetic resonance imaging abnormalities in antibody-mediated encephalitis.

Brain communications·2026
Same author

Quantitative susceptibility mapping demonstrates ageing-related long-term structural brain changes in adult rats after mild ischaemic stroke.

Brain communications·2026
Same author

Multimodal ultra-high-field MRI, clinical, cognitive, and genetic profiles across the ALS-FTD spectrum.

Scientific data·2026
Same author

Authors' reply to 'Comments on dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy'.

British journal of haematology·2026

Related Experiment Video

Updated: Jun 8, 2025

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

3.6K

Deferiprone in Alzheimer Disease: A Randomized Clinical Trial.

Scott Ayton1,2, David Barton3, Bruce Brew4,5

  • 1The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Australia.

JAMA Neurology
|November 4, 2024
PubMed
Summary

This study found that deferiprone, an iron chelator, accelerated cognitive decline in Alzheimer's disease (AD) patients. Lowering brain iron with deferiprone appears detrimental, highlighting the need for cautious therapeutic approaches in AD.

More Related Videos

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.1K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

112

Related Experiment Videos

Last Updated: Jun 8, 2025

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

3.6K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.1K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

112

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Trials

Background:

  • Alzheimer's disease (AD) poses a significant global health challenge, with neurodegeneration being a key pathological feature.
  • Elevated brain iron levels in AD correlate with faster cognitive decline, suggesting iron dysregulation as a potential therapeutic target.

Purpose of the Study:

  • To evaluate the efficacy of deferiprone, a brain-permeable iron chelator, in slowing cognitive decline in individuals with early Alzheimer's disease.

Main Methods:

  • A 12-month, phase 2, double-masked, placebo-controlled randomized clinical trial involving 81 participants with amyloid-confirmed mild cognitive impairment or early AD.
  • Participants received either deferiprone (15 mg/kg twice daily) or a placebo.
  • Primary outcome: cognitive function assessed via a neuropsychological test battery (NTB); Secondary outcomes: changes in brain iron burden (QSM-MRI), brain volume, and safety.

Main Results:

  • Deferiprone treatment accelerated cognitive decline compared to placebo, particularly in executive function.
  • Quantitative susceptibility mapping (QSM) confirmed reduced hippocampal iron in the deferiprone group.
  • Increased frontal lobe volume loss was observed with deferiprone; neutropenia occurred more frequently.

Conclusions:

  • Deferiprone treatment in early AD patients reduced hippocampal iron but accelerated cognitive decline.
  • These findings suggest that iron chelation with deferiprone may be harmful in AD.
  • Further research is needed to understand the complex role of iron in AD pathogenesis and therapeutic interventions.